OPM-1Homo sapiens (Human)Cancer cell line
Also known as: OPM1
No AI-generated summary available for this cell line.
Basic Information
| Database ID | CVCL_5210 |
|---|---|
| Species | Homo sapiens (Human) |
| Tissue Source | Peripheral blood[UBERON:UBERON_0000178] |
Donor Information
| Age | 56 |
|---|---|
| Age Category | Adult |
| Sex | Female |
Disease Information
| Disease | Multiple myeloma |
|---|---|
| Lineage | Lymphoid |
| Subtype | Plasma Cell Myeloma |
| OncoTree Code | PCM |
DepMap Information
| Source Type | Academic lab |
|---|---|
| Source ID | ACH-000057_source |
Known Sequence Variations
| Type | Gene/Protein | Description | Zygosity | Note | Source |
|---|---|---|---|---|---|
| MutationSimple | TP53 | p.Arg175His (c.524G>A) | Unspecified | Somatic mutation acquired during proliferation | from parent cell line YCC-3 |
| MutationSimple | SMAD2 | p.Leu87Arg (c.260T>G) | Heterozygous | - | from parent cell line OPM-2 |
| MutationSimple | FGFR3 | p.Lys650Glu (c.1948A>G) | Heterozygous | - | from parent cell line OPM-2 |
| MutationSimple | CDKN2A | p.His83Tyr (c.247C>T) (p.Ala97Val, c.290C>T) | Unspecified | - | PubMed=11787853 |
Haplotype Information (STR Profile)
Short Tandem Repeat (STR) profile for cell line authentication.
Loading gene expression data...
Publications
Evaluating the efficacy of multiple myeloma cell lines as models for patient tumors via transcriptomic correlation analysis.
Sirota M., Wiita A.P.
Leukemia 34:2754-2765(2020).
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Sellers W.R.
Nature 569:503-508(2019).
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
Cancer Res. 79:1263-1273(2019).
Characterization of MYC translocations in multiple myeloma cell lines.
Dib A., Gabrea A., Glebov O.K., Bergsagel P.L., Kuehl W.M.
J. Natl. Cancer Inst. Monogr. 39:25-31(2008).
Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma.
Stewart A.K., Carpten J.D., Bergsagel P.L.
Cancer Cell 12:131-144(2007).
Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma.
Kuehl W.M., Bergsagel P.L.
Blood 97:729-736(2001).
Malignant hematopoietic cell lines: in vitro models for the study of multiple myeloma and plasma cell leukemia.
Drexler H.G., Matsuo Y.
Leuk. Res. 24:681-703(2000).
Fluorescence in situ hybridization analysis shows the frequent occurrence of 14q32.3 rearrangements with involvement of immunoglobulin switch regions in myeloma cell lines.
Lokhorst H.M., Clevers H.C., Bast B.J.E.G.
Cancer Genet. Cytogenet. 109:99-107(1999).
Two distinct human myeloma cell lines originating from one patient with myeloma.
Tamaki T., Ohnishi M., Tarui S.
Int. J. Cancer 36:241-246(1985).
The leukemia-lymphoma cell line factsbook.";
Drexler H.G.
(In book) ISBN 9780122219702; pp.1-733; Academic Press; London; United Kingdom (2001).
Multiple myeloma cell lines.";
Jernberg-Wiklund H., Nilsson K.
(In book chapter) Human cell culture. Vol. 3. Cancer cell lines part 3; Masters J.R.W., Palsson B.O. (eds.); pp.81-155; Kluwer Academic Publishers; New York; USA (2000).